Glucagon/GLP-1 receptor co-agonists

• US 8,546,327 B2
• Filed: 06/16/2009
• Issued: 10/01/2013
• Est. Priority Date: 06/17/2008
• Status: Expired due to Fees

• Current Assignee: Indiana University Research & Technology Corporation (Indiana University)
• Original Assignee: Indiana University Research & Technology Corporation (Indiana University)
• Inventors: Dimarchi, Richard D., Smiley, David L., Dimarchi, Maria, Chabenne, Joseph, Day, Jonathan, Patterson, James, Ward, Brian
• Primary Examiner(s): Shafer, Shulamith H
• Application Number:
  US12/999,283
• Publication Number:
  US 20110257092A1
• Time in Patent Office: 1,568 Days
• Field of Search: None
• US Class Current: 514/7.2
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07K 14/605 Glucagons

Abstract

Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

Claims

1. A glucagon peptide comprising an amino acid at position 10 which is acylated or alkylated with a C4 to C30 fatty acid;

and an α

, α

-disubstituted amino acid at position 16 of the glucagon peptide or an intramolecular bridge between the side chains of an amino acid at position i and an amino acid at position i+4, wherein i is 12, 16, 20, or 24, wherein the amino acid sequence of the glucagon peptide differs from SEQ ID NO;

1 by no more than ten amino acid modifications.

3. The glucagon peptide of claim 1 or 2, further comprising one or more modifications selected from the group consisting of:

Gln at position 17, Ala at position 18, Glu at position 21, Ile at position 23, and Ala at position 24.

4. The glucagon peptide of claim 1 or 2, comprising a C -terminal amide.

5. The glucagon peptide of claim 1 or 2, comprising an amino acid substitution at position 1, position 2, or positions 1 and 2, wherein the amino acid substitution(s) achieve DPP-IV protease resistance.

6. The glucagon peptide of claim 5, wherein (i) the His at position 1 is substituted with an amino acid selected from the group consisting of:

D-histidine, alpha, alpha-dimethyl imidiazole acetic acid (DMIA), N-methyl histidine, alpha-methyl histidine, imidazole acetic acid, desaminohistidine, hydroxyl-histidine, acetyl-histidine and homo-histidine, (ii) wherein the Ser at position 2 is substituted with an amino acid selected from the group consisting of;

D-serine, alanine, D-alanine, valine, glycine, N-methyl serine, N-methyl alanine, and amino isobutyric acid, or (iii) both (i) and (ii).

7. The glucagon peptide of claim 1 or 2, wherein the amino acid at position 10 of the glucagon peptide is an amino acid of Formula I, Formula II, or Formula III.

8. The glucagon peptide of claim 7, wherein the amino acid of Formula I is Lys.

9. The glucagon peptide of claim 1 or 2, further comprising a spacer between the amino acid at position 10 of the glucagon peptide and the acyl group or alkyl group.

10. The glucagon peptide of claim 9, wherein the spacer is an amino acid or a dipeptide.

11. A conjugate, dimer, or fusion peptide comprising a glucagon peptide of claim 1 or 2.

12. A pharmaceutical composition comprising a glucagon peptide of claim 1 or 2, a dimer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

13. A method of treating diabetes, said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of claim 12 wherein the glucagon peptide of the pharmaceutical composition activates the GLP-1 receptor.

14. A method of reducing weight gain or inducing weight loss, said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of claim 12.

15. The glucagon peptide of claim 1 or 2, comprising:

(a) one, two, or three charged amino acids C-terminal to the amino acid at position 27;

(b) an amino acid selected from the group consisting of glutamic acid, glutamine, homoglutamic acid, homocysteic acid, threonine and glycine, at position 16;

(c) leucine or norleucine at position 27;

(d) a hydrophilic moiety;

(e) or a combination thereof.

16. The glucagon peptide of claim 15, wherein the amino acid at position 28 or 29 is substituted with a charged amino acid.

17. The glucagon peptide of claim 16, wherein the amino acid at position 28 is Asp, Asn, or Lys and the amino acid at position 29 is Gly or Thr.

18. The glucagon peptide of claim 15, comprising a charged amino acid after position 29.

19. The glucagon peptide of claim 1, wherein the C4 to C30 fatty acid is a C8 to C20 fatty acid.

20. The glucagon peptide of claim 19, wherein the acyl group is a C12 to C18 fatty acid.

2. A glucagon peptide that differs from SEQ ID NO:

1 by no more than ten amino acid modifications, comprising an amino isobutyric acid (AIB) at position 16 and an acyl group or alkyl group covalently linked to the amino acid at position 10 of the glucagon peptide, wherein said glucagon peptide exhibits enhanced activity at the GLP-1 receptor as compared to native glucagon.